Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer

Nica, Andra; Lee, Jennifer J.; Hong, Nicole Look; May, Taymaa

doi:10.1016/j.ygyno.2020.09.051

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, maintenance therapy with AIs for low-grade serous EOC has been analyzed from a cost-effectiveness point of view [ 107 ]. The study highlighted that maintenance with letrozole is a cost-effective strategy in women with advanced low-grade serous EOC leading to a clinically-relevant improvement in quality-adjusted life years, life years, and a reduction in the number of recurrences [ 108 ].…”

Section: Aromatase Inhibitorsmentioning

confidence: 99%

Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options

Borella,

Fucina,

Mangherini

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women. Despite advances in diagnosis and treatment, EOC remains a challenging disease to manage, and the 5-year survival rate is still poor. The role of hormone receptors (HRs) in EOC carcinogenesis and prognosis has been actively explored; however, the role of hormone therapy (HT) in the treatment of these tumors is not well established. Most available data on HT mainly come from retrospective series and small early clinical trials. Several of these studies suggest that HT may have a role in adjuvant, maintenance therapy, or in the case of recurrent disease, especially for some subtypes of EOC (e.g., low-grade serous EOC). Furthermore, HT has recently been combined with targeted therapies, but most studies evaluating these combinations are still ongoing. The main aim of this review is to provide an overview of the progress made in the last decade to characterize the biological and prognostic role of HRs for EOC and the developments in their therapeutic targeting through HT.

show abstract

Section: Aromatase Inhibitorsmentioning

confidence: 99%